DK1463735T3 - Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider - Google Patents

Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider

Info

Publication number
DK1463735T3
DK1463735T3 DK02784979T DK02784979T DK1463735T3 DK 1463735 T3 DK1463735 T3 DK 1463735T3 DK 02784979 T DK02784979 T DK 02784979T DK 02784979 T DK02784979 T DK 02784979T DK 1463735 T3 DK1463735 T3 DK 1463735T3
Authority
DK
Denmark
Prior art keywords
imidazo
formula
sulfonamides
thiadiazole
thiadiazole sulfonamides
Prior art date
Application number
DK02784979T
Other languages
Danish (da)
English (en)
Inventor
James B Jaquith
Gerald Villeneuve
Alain Boudreault
Stephen Morris
John W Gillard
Kimberly Hewitt
Nicholas H Marsh
Jon Durkin
Original Assignee
Aegera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegera Therapeutics Inc filed Critical Aegera Therapeutics Inc
Application granted granted Critical
Publication of DK1463735T3 publication Critical patent/DK1463735T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
DK02784979T 2001-12-14 2002-12-16 Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider DK1463735T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002364985A CA2364985A1 (en) 2001-12-14 2001-12-14 Imidazo(2,1-b)thiadiazole sulfonamides
PCT/CA2002/001942 WO2003051890A1 (en) 2001-12-14 2002-12-16 Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides

Publications (1)

Publication Number Publication Date
DK1463735T3 true DK1463735T3 (da) 2009-12-14

Family

ID=4170835

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02784979T DK1463735T3 (da) 2001-12-14 2002-12-16 Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider

Country Status (11)

Country Link
US (8) US7230019B2 (de)
EP (1) EP1463735B1 (de)
JP (2) JP2005519882A (de)
AT (1) ATE439363T1 (de)
AU (1) AU2002350333B2 (de)
CA (1) CA2364985A1 (de)
DE (1) DE60233350D1 (de)
DK (1) DK1463735T3 (de)
ES (1) ES2329882T3 (de)
PT (1) PT1463735E (de)
WO (1) WO2003051890A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
WO2004111060A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics Inc. IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES
EP1636242A1 (de) * 2003-06-13 2006-03-22 Aegera Therapeutics Inc. Acylierte und nicht-acylierte imidazo(2,1-b)-1,3,4-thiadiazol-2-sulfonamide und deren verwendung
WO2007034278A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists
US20090179638A1 (en) * 2006-02-01 2009-07-16 Aegera Therapeutics Inc. Assay for identifying inhibitors of neuronal apoptotic pathways
AU2008209320B2 (en) * 2007-01-25 2013-05-30 NAIA Metabolic, Inc. Insulin sensitisers and methods of treatment
EP2193133B1 (de) * 2007-09-27 2015-08-19 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Imidazolothiadiazole zur verwendung als proteinkinaseinhibitoren
ES2548571T3 (es) 2009-04-02 2015-10-19 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Derivados de imidazo[2,1-b][1,3,4]tiadiazol
US8771324B2 (en) 2011-05-27 2014-07-08 Globus Medical, Inc. Securing fasteners
EP2855489B1 (de) 2012-04-26 2017-01-04 Bristol-Myers Squibb Company Imidazothiadiazol- und imidazopyridazinderivate als proteaseaktivierte rezeptor 4 (par4)-inhibitoren zur behandlung von thrombozytenaggregation
EA201491967A1 (ru) 2012-04-26 2015-03-31 Бристол-Майерс Сквибб Компани Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов
SMT201700457T1 (it) 2012-04-26 2017-11-15 Bristol Myers Squibb Co DERlVATI IMIDAZOTIADIAZOLICI E IMIDAZOPIRAZINICI COME INIBITORI DEL RECETTORE ATTIVATO DA PROTEASI 4 (PAR4) PER IL TRATTAMENTO DELL'AGGREGAZIONE PIASTRINICA
EP3053908B1 (de) * 2013-09-30 2018-12-19 FUJIFILM Corporation Verfahren zur herstellung einer alpha-halogenoacetophenonverbindung und alpha-bromoacetophenonverbindung
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
WO2017184520A1 (en) * 2016-04-18 2017-10-26 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
KR20210052435A (ko) 2018-08-30 2021-05-10 니혼 메디피직스 가부시키가이샤 방사성 이미다조티아디아졸 유도체 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US52514A (en) * 1866-02-13 Stove-pipe damper
GB1464259A (en) * 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
WO1999062880A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
CA2379375A1 (en) * 2002-03-28 2003-09-28 Apotex Inc. Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases

Also Published As

Publication number Publication date
US7714003B2 (en) 2010-05-11
US20070238768A1 (en) 2007-10-11
US7772260B2 (en) 2010-08-10
PT1463735E (pt) 2009-10-15
JP2010106030A (ja) 2010-05-13
US7741349B2 (en) 2010-06-22
US20070088059A1 (en) 2007-04-19
WO2003051890A1 (en) 2003-06-26
US7230019B2 (en) 2007-06-12
DE60233350D1 (de) 2009-09-24
JP2005519882A (ja) 2005-07-07
ATE439363T1 (de) 2009-08-15
ES2329882T3 (es) 2009-12-02
US20070265319A1 (en) 2007-11-15
AU2002350333A1 (en) 2003-06-30
US20090042953A1 (en) 2009-02-12
AU2002350333B2 (en) 2008-08-21
US7700635B2 (en) 2010-04-20
US20070238766A1 (en) 2007-10-11
US20050069492A1 (en) 2005-03-31
US20070021416A1 (en) 2007-01-25
CA2364985A1 (en) 2003-06-14
EP1463735B1 (de) 2009-08-12
US20070021476A1 (en) 2007-01-25
EP1463735A1 (de) 2004-10-06

Similar Documents

Publication Publication Date Title
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
GB0225474D0 (en) Therapeutic agents
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
BR0317020A (pt) Derivados de hidroxietilamina para o tratamento de doença de alzheimer
GB0223038D0 (en) Therapeutic compounds
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
BRPI0316438C1 (pt) uso de eritropoietina em doenças cardíacas
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
BR0316169A (pt) Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
DE60224928D1 (de) Dermatologische und kosmetische zusammensetzungen enthaltend ein furfurylderivat
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
GB0111186D0 (en) Novel compounds
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases